Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

B7-H4 antibody data presented at ESMO 2017
October 2017
SHARING OPTIONS:

SOUTH SAN FRANCISCO, Calif.—Biotechnology company Five Prime Therapeutics Inc. presented an oral poster discussion recently at the European Society for Medical Oncology (ESMO) 2017 Congress on FPA150, its novel B7-H4 therapeutic antibody. Five Prime is currently developing the monoclonal antibody, which has shown potent antibody-dependent cell-mediated cytotoxicity and T cell checkpoint blockade activity in vitro and notable dose-dependent antitumor efficacy in vivo.
 
“B7-H4 represents an ideal target for a therapeutic antibody,” said Dr. Bryan Irving, senior vice president of research at Five Prime. “B7-H4 is expressed in several solid tumor types not typically associated with PD-L1 expression and its expression negatively correlates with patient outcome. Moreover, B7-H4 represents a T cell checkpoint ligand that is not currently targeted by other immuno-oncology agents.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.